Day: November 15, 2023

Generated Robust 61% Year-over-Year Revenue Growth in Q3 2023 Nearing Breakeven Operating Income, Achieved Positive Adjusted EBITDA, with Cash Flow from Operations Exceeding $1 Million Conference Call to be Held Today at 8:30 AM EST BURLINGTON, Mass. and JERUSALEM, Nov. 15, 2023 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported third quarter 2023 financial results and provided an operational update. Recent Financial and Operational HighlightsFor the three months ended September 30, 2023, revenues were $8.3 million, a 61% increase as compared to the third quarter of 2022 and a 6% increase as compared to the second quarter of 2023. Gross margin for the third quarter of 2023 was 74%, steady from...

HOUSTON, TX, Nov. 15, 2023 (GLOBE NEWSWIRE) — Prairie Operating Co. (OTCQB: PROP; the “Company” or “Prairie”) announced today that it has received $12 million in proceeds from the exercise of warrants to purchase 2 million shares of common stock (the “Warrants”).  These in-the-money Warrants were strategically exercised by Watermill Capital Partners and its affiliates, a sophisticated long-term focused capital investor based in Australia.  Watermill Capital Partners and its affiliates have an extensive and successful track record of investing in growth-oriented businesses. Mr. Greg O’Neill, Managing Director of Watermill Capital Partners and its affiliates, commented, “The Company’s outsized accomplishments, in such a short period of time, provides Watermill Capital Partners with the ability to accelerate and optimize our long-term...

– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will host conference call and webcast today, November 15th at 8:30 AM ET OCALA, Fla., Nov. 15, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported financial results for the third quarter 2023 and provided a business update. As previously announced, the Company will host a conference call and webcast today, Wednesday, November 15, 2023, at 8:30 AM ET (details below). “Our team continues to make significant strides in the advancement of Ampligen® through our active human clinical studies in multiple indications, including pancreatic cancer, ovarian cancer and post-COVID conditions. Our clinical...

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) — Salona Global Medical Device Corporation (the ‎‎“Company”) (TSXV:SGMD), soon to be renamed Evome Medical Technologies Inc., today announced financial highlights for its third quarter, ending September 30, 2023. Financial Headlines RevenuesGenerated $19,647,489 in revenue for the quarter ending September 30, 2023.18.5% increase from the previous quarter. 78.3% increase from the same period in the prior year.ProfitsGenerated $7,268,163 in gross profit for the quarter ending September 30, 2023.29.0% increase from the previous quarter. 128.4% increase from the same period in the prior year.Improved gross profit margins to 37% from 34% in the previous quarter. Generated $749,425 in positive Adjusted EBITDA (defined below) for the quarter ending September 30, 2023 as compared...

TORONTO, Nov. 15, 2023 (GLOBE NEWSWIRE) — DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a generative artificial intelligence healthcare company, is pleased to announce it has been accepted into the Southern Ontario Pharmaceutical & Health Innovation Ecosystem (“SOPHIE”) Program to accelerate the clinical and commercialization efforts in Canada for the Company’s CERVAI™ Brain Health AI Platform. The SOPHIE program supports collaborative projects for Ontario-based life science firms in the later stages of commercialization. DiagnaMed can leverage funding to work directly with an academic or hospital partner in Hamilton’s ecosystem, such as McMaster University, Mohawk College, Hamilton Health Sciences, and St Joseph’s Health Centre Foundation. A world first, CERVAI™ consists...

Samira Naraghi, VP, Product Strategy at EnovixEnovix Vice President of Product Strategy Samira Naraghi Appointed to Consumer Technology Association Board of Industry LeadersFREMONT, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX), an advanced silicon battery company, today announced that Samira Naraghi, Enovix’s Vice President of Product Strategy, has been appointed to the 2024 Consumer Technology Association (CTA)® Board of Industry Leaders. CTA is the trade association representing the $505 billion U.S. consumer technology industry, which supports more than 18 million U.S. jobs. Its Board of Industry Leaders comprises of executives who are experienced leaders from CTA’s member companies and who have broad experience in the consumer technology sector and represent the industry’s...

GREENWICH, Conn., Nov. 15, 2023 (GLOBE NEWSWIRE) — American Battery Materials, Inc. (OTC Pink: BLTH) (“ABM”, the “Company”), an environmentally responsible minerals exploration and development company focused on direct lithium extraction (DLE) and other critical minerals for the global energy transition, today issued a clarification of the status of the Company’s 1-for-300 reverse stock split. As announced yesterday by FINRA on its Daily List, FINRA completed its review and the reverse stock split was to become effective on the OTC Marketplace at 8:00 AM Eastern time on November 15, 2023. The Company was subsequently informed by FINRA that the Company’s transfer agent, Equiniti, failed to confirm with DTC that it was engaged to serve as the exchange agent to process the reverse stock split. As such, the reverse stock split has...

– $6.85 million upfront investment provides $23 million total cash runway into second half 2025 – – Financing allows for focused commercial team to bring Femasys’ infertility-related products to women in the U.S. – – Additional financing supports the advancement of Femasys’ lead product candidate, FemBloc® for permanent birth control, to initial clinical data readout – ATLANTA, Nov. 15, 2023 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced a strategic upfront investment of $6.85 million by public biotech company, PharmaCyte Biotech,...

Map 1Map 1: Gayna Project Location Relative to Fireweed’s Flagship Macpass and Mactung Projects.Map 2Map 2: Gayna Project Geology.Map 3Map 3: Gayna Project Claims and Historical Drill Collars and Cross Section Locations.Cross section A–A’Cross section A–A’: Gravity highs coincident with both shallowly-buried margins of the reef and with high magnitude anomalies associated with the “A” and “F” showings.Cross section B–B’Cross section B–B’: gravity high coincident with shallowly-buried, reef-margin.Map 4Map 4: 2022 and 2023 Ground Gravity Survey Results.Photo 1Photo 1: Gayna Project ‘A’ showing, sample. Upper-Host sub-rounded dolostone breccia, matrix infilled with dolomite, calcite, crystalline red and green sphalerite, and metallic galena.VANCOUVER, British Columbia,...

LENEXA, Kansas, Nov. 15, 2023 (GLOBE NEWSWIRE) — Digital Ally, Inc. (Nasdaq: DGLY) (the “Company” or “our”), today announced its operating results for the third quarter 2023. An investor conference call is scheduled for 11:15 a.m. EDT on Wednesday, November 15, 2023 (see details below). All share and price per share information in this press release has been adjusted to reflect the Company’s 1-for-20 reverse stock split, which was effective on February 6, 2023. Highlights for the third quarter ended September 30, 2023● Total revenues for the three months ended September 30, 2023 were $6,337,699, a decrease of $2,146,454, or (25%), as compared to $8,484,153 for the three months ended September 30, 2022. Overall product revenues were $2,095,237 for the three months ended September 30, 2023, a decrease of $967,136, or (32%), as...